Research Area

Basic Projects

In vitro System for Pharmacokinetics

Our research focuses on a comprehensive evaluation of drug pharmacokinetics, covering absorption, distribution, metabolism, and excretion (ADME):

Absorption: We utilize in vitro permeability assays such as PAMPA, Caco-2, and MDCK-II to predict drug absorption and intestinal permeability.
Distribution: Plasma protein binding assays and blood-to-plasma ratio measurements help assess drug distribution within the body.
Metabolism: We conduct liver microsomal stability studies (CYP, UGT) and plasma stability assays to evaluate metabolic clearance and bioavailability.
Excretion: Our studies include renal and biliary excretion analysis, incorporating transporter assays (e.g., P-gp, BCRP, OAT, OCT) and metabolic byproduct profiling to predict drug elimination pathways.

In vivo System for Pharmacokinetics

Our research focuses on in vivo pharmacokinetic studies to evaluate drug behavior in biological systems across various modalities:

Modality: We study both small molecule drugs and peptide-based therapeutics to assess their pharmacokinetic properties.
Animal Models: Our pharmacokinetic studies are conducted in preclinical species, including mice, rats, dogs, and monkeys, to predict human drug exposure and optimize dosing strategies.
Tissue Distribution: We analyze drug distribution across various tissues to understand biodistribution, target engagement, and potential off-target effects.

LC-MS/MS system : Aglient 6430, SCIEX 3200, SCIEX 4000, SCIEX 6500

In silico System for Pharmacokinetics

Our research focuses on a wide range of pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) modeling approaches to enhance drug development and translational predictions:

Non-Compartmental Analysis (NCA): We perform NCA to determine key pharmacokinetic parameters without assuming specific compartmental structures.
Compartmental Modeling and Simulation: We utilize compartmental models to describe drug kinetics and optimize dosing regimens.
Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation: Our PBPK models integrate physiological and biochemical parameters to predict drug behavior across different populations and conditions.
PK-PD Modeling and Simulation: We develop PK-PD models to link drug exposure with pharmacological effects, supporting efficacy and safety assessments.
Inter-Species Pharmacokinetic Scaling: We use allometric scaling and mechanistic modeling to translate animal pharmacokinetic data to human predictions.
First-in-Human (FIH) Dose Projection: Our research includes FIH dose estimation based on preclinical data to guide early clinical trial designs.
Drug-Drug Interaction (DDI): We study potential DDIs using in vitro and in silico approaches to predict metabolic and transporter-mediated interactions.
In Vitro-In Vivo Correlation (IVIVC): We establish IVIVC to enhance the predictability of in vitro findings for in vivo drug behavior.
In Vitro-In Vivo Extrapolation (IVIVE): We utilize IVIVE methods to predict human pharmacokinetics from in vitro experimental data.

X-PK Projects

Theo-PK

Theoretical Pharmacokinetics (Theoretical PK)

Our research in Theoretical Pharmacokinetics (PK) focuses on developing mathematical frameworks and computational models to describe and predict drug behavior in biological systems. By exploring fundamental principles of absorption, distribution, metabolism, and excretion (ADME), we aim to construct simplified yet robust models that provide mechanistic insights, support hypothesis generation, and guide experimental design in drug development.

MPS-PK

Pharmacokinetic Analysis and Modeling Using Microphysiological Systems (MPS)

Our research focuses on pharmacokinetic analysis and modeling through microphysiological systems (MPS). By integrating advanced MPS technology, we aim to enhance the prediction of drug absorption, distribution, metabolism, and excretion (ADME) in a physiologically relevant manner. Our work bridges the gap between in vitro studies and clinical outcomes, contributing to more accurate drug development and personalized medicine.

Neuro-PK

Pharmacokinetic Evaluation and Modeling for the Central Nervous System (CNS)

Our research focuses on pharmacokinetic evaluation and modeling for the central nervous system (CNS). By leveraging advanced methodologies, including microphysiological systems (MPS), we aim to enhance the prediction of drug penetration across the blood-brain barrier (BBB) and CNS drug distribution. Our work contributes to the development of effective therapeutics for neurological disorders by improving the accuracy of drug efficacy and safety assessments.

Astro-PK

Pharmacokinetic Simulation for Astronauts in Space

Our research explores pharmacokinetic simulation to understand drug behavior in microgravity environments. By integrating physiological modeling and space-specific factors, we aim to predict drug absorption, distribution, metabolism, and excretion (ADME) in astronauts. This work contributes to the development of optimized medication strategies for space missions, ensuring effective treatment and crew health during extended space travel.

Digital-PK

Web-Based Pharmacokinetic Analysis

Our research focuses on developing web-based platforms for pharmacokinetic analysis. By integrating computational modeling and cloud-based systems, we aim to provide user-friendly, accessible tools for drug absorption, distribution, metabolism, and excretion (ADME) analysis. This approach enhances efficiency in pharmacokinetic studies, supporting drug development and personalized medicine through real-time data analysis and simulation.

AI-PK

AI-Integrated Pharmacokinetic Modeling and Simulation

Our research focuses on the integration of artificial intelligence (AI) into pharmacokinetic modeling and simulation. By leveraging machine learning and data-driven approaches, we aim to enhance the prediction of drug absorption, distribution, metabolism, and excretion (ADME). This AI-powered framework improves the accuracy and efficiency of pharmacokinetic analysis, facilitating drug development and personalized medicine.

Quantum-PK

Quantum Computing-Integrated Pharmacokinetic Modeling and Simulation

Our research integrates quantum computing into pharmacokinetic (PK) modeling to enhance drug behavior predictions. By leveraging quantum algorithms and molecular simulations, we refine absorption, distribution, metabolism, and excretion (ADME) predictions, optimize drug-receptor interactions, and improve PK-PD modeling, enabling faster simulations and more precise drug development..

Page updated

Google Sites

Report abuse